Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
NCT07512362
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mild Cognitive Impairment
- Early Alzheimer's Disease
- AD-MCI
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bernard (Barry) Baumel
- Last updated on ClinicalTrials.gov
- May 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- University of Miami Department of Neurology · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.